What is SimBioSys?
SimBioSys operates at the critical intersection of biology and technology, deploying advanced mechanistic models to create spatially resolved virtual replicas of individual tumors. By leveraging standard-of-care diagnostic data such as imaging and pathology, the company's TumorScope platform enables researchers and clinicians to predict therapeutic responses and identify mechanisms of resistance with high precision. Unlike traditional genomic-focused approaches, SimBioSys offers a comprehensive, data-driven methodology that complements existing precision medicine workflows, effectively virtualizing the disease to empower personalized treatment strategies. This unique market position allows the company to bypass many of the barriers typically associated with adopting new standards of care in oncology.
How much funding has SimBioSys raised?
SimBioSys has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2021): $15M with participation from Genoa Ventures, AV8 Ventures, Northpond Ventures, Mayo Clinic, and Heritage Medical Group
Key Investors in SimBioSys
Genoa Ventures
Genoa Ventures is an investment firm focused on early-stage companies that are innovating at the intersection of biology and technology, providing strategic support to accelerate bioconvergence.
AV8 Ventures
AV8 Ventures supports early-stage start-ups in sectors such as healthcare and deep-tech, partnering with founders to build category-defining companies.
Mayo Clinic
Mayo Clinic is a nonprofit global healthcare organization that integrates clinical practice, education, and medical research to drive healthcare innovation.
What's next for SimBioSys?
Following this major enterprise-level funding, SimBioSys is poised to accelerate the clinical validation and commercial deployment of its simulation technology. The strategic roadmap likely involves expanding the utility of TumorScope across diverse cancer types and deepening partnerships with major healthcare institutions to integrate these computational insights into routine clinical practice. By focusing on drug sensitivity, metabolism, and mechanical forces within the tumor microenvironment, the company aims to establish a new paradigm in oncology where treatment decisions are informed by predictive, patient-specific simulations rather than generalized protocols. This growth phase will be critical in demonstrating the long-term efficacy and scalability of their bioconvergence model in a competitive precision medicine landscape.
See full SimBioSys company page
